跳转至内容
Merck
CN

45706

华法林

PESTANAL®, analytical standard

别名:

4-羟基-3-(3-氧代-1-苯基丁基)-2H-1-苯并吡喃-2-酮, 杀鼠灵钠

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C19H16O4
化学文摘社编号:
81-81-2
分子量:
308.33
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329756915
EC Number:
201-377-6
Beilstein/REAXYS Number:
8868198
MDL number:
MFCD00006854

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

华法林, PESTANAL®, analytical standard

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

grade

analytical standard

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

162-164 °C (lit.)

application(s)

agriculture
environmental

format

neat

Quality Level

100

Gene Information

human ... VKORC1(79001)

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

华法林是一种常用于预防血栓形成和血栓栓塞的抗凝剂。 其已在许多中风和肺纤维化患者研究中使用。 它已用于研究潜在风险以及与其他药物和食物的相互作用。
有关合适的仪器技术的更多信息，请参阅产品的分析证书。想要获得更多支持，请联系技术服务部。

Biochem/physiol Actions

华法林由两种活性对映体R和S形式的外消旋混合物组成。 华法林比普通抗凝肝素作用慢。 华法令可抑制钙依赖性凝血因子II、VII、IX和X的生物活性形式的维生素K依赖性合成。它可抑制调节因子蛋白C、蛋白S和蛋白Z。

Disclaimer

仅限于专业用户。注意 — 避免接触 — 使用前请阅读说明书。

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

target_organs

Blood

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

法规信息

危险化学品
农药列管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCM4467
BCCH4004
BCBV7416
BCBV3285

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
James D Douketis et al.
Thrombosis and haemostasis, 113(3), 625-632 (2014-12-05)
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for
Matthew W Sherwood et al.
Circulation, 129(18), 1850-1859 (2014-02-21)
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and
Shinji Kamisuki et al.
Journal of medicinal chemistry, 54(13), 4923-4927 (2011-05-13)
Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification
查看所有相关文献

实验方案

HPLC Analysis of Warfarin Anticoagulant on Ascentis C18

HPLC Analysis of Warfarin™ Anticoagulant on Ascentis® C18

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持